Sign In
Buy CAPR
$3.85
-0.240 (-5.87%)
At Close: Aug 10, 2026
Deadline Approaching: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
04:00pm, Tuesday, 04'th Aug 2026
Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of inve
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Capricor Therapeutics, Inc. (NASDAQ: CAPR) (
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of inv
Deadline Approaching: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged to Contact Law Offices of Howard G. Smith
03:05pm, Tuesday, 04'th Aug 2026
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors wh
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or ac
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Tuesday, 04'th Aug 2026
New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors.
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between De
CAPR Stock Drop: Capricor Therapeutics Clinical Data Leads to 64% Stock Drop and Securities Fraud Class Action for Investors
06:36am, Tuesday, 04'th Aug 2026
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading t
NEW YORK--(BUSINESS WIRE)---- $CAPR #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Capricor Therapeutics, In
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
05:45pm, Monday, 03'rd Aug 2026
NEW YORK, Aug. 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (N
NEW YORK--(BUSINESS WIRE)---- $CAPR #BFA--Capricor Therapeutics Sued for Securities Fraud after Stock Drops 64% Leading to Securities Fraud Case – Investors Urged to Contact BFA Law.
New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company
SAN DIEGO, Aug. 3, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ
